ZURA Healthcare

Zura Bio Limited

$3.99+1.27%

Price as of close on Nov 3, 2026 · Financials updated Oct 2, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 382.4M USD
Enterprise value: 177.2M USD
Full-time employees: 40

Overall health

Not enough data: too little is reported yet for an overall view

Only 1 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Zura Bio looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Zura Bio reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

—

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-22.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-52.3%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-17.0%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield51.5%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Zura Bio

Is Zura Bio getting weaker?: Its latest SEC filing (Aug 11, 2026) showed no major changes.
How is Zura Bio valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -22.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -22.4% vs peers 1.5% (weaker than 100% of peers).
Is Zura Bio growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Zura Bio?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Zura Bio?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 11, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Net income (12 months)	−75.4M USD	−85.7M USD	+13.7%
Free cash flow (12 months)	−72.8M USD	−64.9M USD	−10.7%
Cash	225.6M USD	205.1M USD	−9.1%
Shares outstanding	95.0M	95.8M	+0.9%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-488.4%	-59.9%	-29.2%	-60.2%	▼ 31 pts
Return on equity (ROE)	—	-101.7%	-35.7%	-67.6%	▼ 32 pts
Current ratio	0.12×	4.97×	9.16×	9.05×	▼ 1.2%

ZURA price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Zura Bio looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Zura Bio reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Zura Bio

Is Zura Bio getting weaker?

Its latest SEC filing (Aug 11, 2026) showed no major changes.

How is Zura Bio valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -22.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -22.4% vs peers 1.5% (weaker than 100% of peers).

Is Zura Bio growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Zura Bio?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Zura Bio?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

Previous quarter

Latest quarter

Change

Net income (12 months)

−75.4M USD

−85.7M USD

+13.7%

Free cash flow (12 months)

−72.8M USD

−64.9M USD

−10.7%

Cash

225.6M USD

205.1M USD

−9.1%

Shares outstanding

95.0M

95.8M

+0.9%

Key ratios

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-488.4%

-59.9%

-29.2%

-60.2%

▼ 31 pts

Return on equity (ROE)

—

-101.7%

-35.7%

-67.6%

▼ 32 pts

Current ratio

0.12×

4.97×

9.16×

9.05×

▼ 1.2%